EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advances in reversible covalent kinase inhibitors

Zheng Zhao iD, Philip E Bourne

Medicinal Research Reviews · 2025-03 · 45 (2) · 629-653

DOI: 10.1002/med.22084 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, online erschienen am 17.09.2024. Verfasst von Zheng Zhao und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Data Science, University of Virginia, Charlottesville, Virginia, USA. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Protein Kinases. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Virginia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Reversible covalent kinase inhibitors (RCKIs) are a class of novel kinase inhibitors attracting increasing attention because they simultaneously show the selectivity of covalent kinase inhibitors yet avoid permanent protein‐modification‐induced adverse effects. Over the last decade, RCKIs have been reported to target different kinases, including Atypical group of kinases. Currently, three RCKIs are undergoing clinical trials. Here, advances in RCKIs are reviewed to systematically summarize the characteristics of electrophilic groups, chemical scaffolds, nucleophilic residues, and binding modes. In so doing, we integrate key insights into privileged electrophiles, the distribution of nucleophiles, and hence effective design strategies for the development of RCKIs. Finally, we provide a further perspective on future design strategies for RCKIs, including those that target proteins other than kinases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsProtein KinasesHumansAnimals

Stichwörter der Autor:innen

binding modesdrug discoverykinase inhibitorsprivileged warheadsreversible‐covalent kinase inhibitors

Substanzen

Protein Kinase InhibitorsProtein Kinases

Autor:innen und Institutionen

  • School of Data Science, University of Virginia, Charlottesville, Virginia, USA.
  • Department of Biomedical Engineering, University of Virginia, Charlottesville, Virginia, USA.

ORCID-Profile: Zheng Zhao

Förderung

  • University of Virginia

Zitieren

APA

Zhao, Z., & Bourne, P. E. (2025). Advances in reversible covalent kinase inhibitors. Medicinal Research Reviews, 45(2), 629-653. https://doi.org/10.1002/med.22084

Vancouver

Zhao Z, Bourne PE. Advances in reversible covalent kinase inhibitors. Medicinal Research Reviews. 2025;45(2):629-653. doi:10.1002/med.22084

BibTeX
@article{Zhao2025,
  author = {Zhao, Zheng and Bourne, Philip E},
  title = {Advances in reversible covalent kinase inhibitors},
  journal = {Medicinal Research Reviews},
  year = {2025},
  volume = {45},
  number = {2},
  pages = {629--653},
  doi = {10.1002/med.22084}
}
Kostenlos starten →